All Stories

  1. Isolated Epicardial Langerhans Cell Histiocytosis in a Neonate With Complete Spontaneous Regression
  2. Langerhans-Zell-Histiozytose
  3. Tumoren der Schilddrüse
  4. Leukocyte Adhesion Defect Type I: Delayed Umbilical Cord Separation, a Surplus of Cells, and a Deficit of Defense
  5. Disease response criteria in Langerhans cell histiocytosis: a global view
  6. The Diligent Lego Player with Talocalcaneal Callosities
  7. The ECHO recommendations for dealing with vinblastine shortage affecting standard treatment of systemic Langerhans cell histiocytosis
  8. Therapiestrategien bei Kindern und Jugendlichen mit Langerhanszell Histiozytosen
  9. Aktualisierte AWMF Leitlinie zur Diagnostik und Therapie der Langerhanszell Histiozytose (LCH) im Kindes- und Jugendalter
  10. Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study
  11. Outcome of haematopoietic cell transplantation in children with lysosomal acid lipase deficiency: a study on behalf of the EBMT Inborn Errors Working Party
  12. Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE
  13. Concurrence of a kinase‐dead BRAF and an oncogenic KRAS gain‐of‐function mutation in juvenile xanthogranuloma
  14. Whole‐body magnetic resonance imaging for staging Langerhans cell histiocytosis in children and young adults
  15. Fröschlein im Mund: eine Blickdiagnose?
  16. SARS-CoV-2 Associated Pediatric Inflammatory Multisystem Syndrome With a High Prevalence of Myocarditis – A Multicenter Evaluation of Clinical and Laboratory Characteristics, Treatment and Outcome
  17. Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis
  18. Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis
  19. Training von Basisreanimationsmaßnahmen (Newborn Life Support, Paediatric Basic Life Support)
  20. EVOLUTION OF TREATMENT OF CHILDREN WITH LANGERHANS CELL HISTIOCYTOSIS
  21. Langerhans Cell Histiocytosis of the Orbit: Spectrum of Clinical and Imaging Findings
  22. Novel Compound Heterozygous Mutations in Two Families With Bernard–Soulier Syndrome
  23. Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study
  24. Hemolytic anemia due to the unstable hemoglobin Wien: manifestations and long-term course in the largest pedigree identified to date
  25. The coming of age of Langerhans cell histiocytosis
  26. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study
  27. Epigenomics and Single-Cell Sequencing Define a Developmental Hierarchy in Langerhans Cell Histiocytosis
  28. Low mortality and short‐term morbidity in very preterm infants in Austria 2011–2016
  29. Mycoplasma-pneumoniae -assoziierte Mukositis mit Hautbeteiligung - ein Fallbericht
  30. Successful Treatment with SCIG of a Child with Refractory Chronic ITP
  31. Mycoplasma pneumoniae -associated mucositis with cutaneous involvement - a case report
  32. Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis
  33. Langerhans cell histiocytosis in children
  34. Langerhans cell histiocytosis in children
  35. An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy
  36. Histiozytäre Erkrankungen
  37. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study
  38. Effective Immunological Guidance of Genetic Analyses Including Exome Sequencing in Patients Evaluated for Hemophagocytic Lymphohistiocytosis
  39. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults
  40. Central Nervous System Langerhans Cell Histiocytosis
  41. Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH
  42. The Non-Langerhans Cell Histiocytoses (Rare Histiocytoses) – Clinical Aspects and Therapeutic Approaches
  43. Insights into the pathogenesis of Langerhans cell histiocytosis
  44. Current treatment of Langerhans cell histiocytosis
  45. Management of chronic immune thrombocytopenia in children and adolescents: lessons from an Austrian national cross-sectional study of 81 patients
  46. Two Novel Missense Mutations and a 5bp Deletion in the Erythroid-Specific Promoter of thePKLRGene in Two Unrelated Patients With Pyruvate Kinase Deficient Transfusion-Dependent Chronic Nonspherocytic Hemolytic Anemia
  47. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study
  48. Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies
  49. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents
  50. Treatment of Langerhans cell histiocytosis: it is time to learn from the past
  51. Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood
  52. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel
  53. Polycythaemia-inducing mutations in the erythropoietin receptor (EPOR): mechanism and function as elucidated by epidermal growth factor receptor-EPOR chimeras
  54. Histiozytosen
  55. Polycythemia-Inducing Mutations In The Erythropoietin Receptor (EPOR): Mechanism and Function Elucidated By EGFR– EPOR Chimeras
  56. Genetic Basis of Congenital Erythrocytosis
  57. Sequential decisions on FAS sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopenia
  58. Hypertrophic Obstructive Cardiomyopathy in an Infant With an Adrenocortical Tumor
  59. Radiological features of thymic langerhans cell histiocytosis
  60. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis
  61. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens
  62. Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease
  63. Stem cell transplantation after reduced-intensity conditioning for sickle cell disease
  64. Notch is active in Langerhans cell histiocytosis and confers pathognomonic features on dendritic cells
  65. Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years
  66. Isolated cutaneous Langerhans cell histiocytosis in a premature baby: What is the optimal approach?
  67. Langerhans-Zell-Histiozytose
  68. Pulmonary Involvement in Pediatric-Onset Multisystem Langerhans Cell Histiocytosis: Effect on Course and Outcome
  69. Langerhans cell histiocytosis: pragmatic empirism on the road to rational cure
  70. Long‐term outcome of hypothalamic pituitary tumors in Langerhans cell histiocytosis
  71. Kopf- und Halstumore im Kindesalter
  72. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group
  73. Variant alleles of cytokine genes influence risk and clinical course of Langerhans cell histiocytosis
  74. Multisystem Langerhans Cell Histiocytosis in Children
  75. Clinical and immunological overlap between autoimmune lymphoproliferative syndrome and common variable immunodeficiency
  76. Evaluating Bleeding Severity in Children with newly Diagnosed Immune Thrombocytopenia: A Pilot Study
  77. Novel TMPRSS6 mutations associated with iron-refractory iron deficiency anemia (IRIDA)
  78. Transcobalamin II deficiency at birth
  79. Subcutaneous anti-d globulin application is a safe treatment option of immune thrombocytopenia in children
  80. Diabetes insipidus in Langerhans cell histiocytosis: When is treatment indicated?
  81. Granulocyte Transfusions in Children and Young Adults
  82. A Syndrome with Congenital Neutropenia and Mutations inG6PC3
  83. Reactivations in Multisystem Langerhans Cell Histiocytosis: Data of the International LCH Registry
  84. Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera
  85. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification
  86. Bone marrow assessment in Langerhans cell histiocytosis
  87. Extramedullary plasmacytoma of the adenoids
  88. Importance of allogeneic T-cells for disease control after stem cell transplantation for high-risk Langerhans cell histiocytosis
  89. Severe Anemia Owing to Occult Pulmonary Hemorrhage
  90. Central nervous system‐related permanent consequences in patients with Langerhans cell histiocytosis
  91. Critical issues concerning splenectomy for chronic idiopathic thrombocytopenic purpura in childhood
  92. Skelettbefall bei Langerhanszellhistiozytose
  93. Central diabetes insipidus: Is it Langerhans cell histiocytosis of the pituitary stalk? A diagnostic pitfall
  94. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning
  95. Modern Imaging Methods for the Assessment of Langerhans' Cell Histiocytosis—Associated Neurodegenerative Syndrome: Case Report
  96. Risk factors for diabetes insipidus in langerhans cell histiocytosis
  97. Histiocytosis following T-acute lymphoblastic leukemia: A BFM study
  98. Langerhans cell histiocytosis in neonates
  99. Pineal gland abnormalities in Langerhans cell histiocytosis
  100. Central diabetes insipidus as presenting symptom of Langerhans cell histiocytosis
  101. Course and clinical impact of magnetic resonance imaging findings in diabetes insipidus associated with Langerhans cell histiocytosis
  102. Demonstration of CD1a positive cells in the cerebrospinal fluid—A clue to diagnosis of isolated Langerhans cell histiocytosis of the hypothalamic—pituitary axis?
  103. IVIG Treatment of Adenovirus Infection-Associated Macrophage Activation Syndrome in a Two-Year-Old Boy: Case Report and Review of the Literature
  104. Immunosuppressive treatment for chemotherapy-resistant multisystem langerhans cell histiocytosis
  105. IVIG Treatment of Adenovirus Infection-Associated Macrophage Activation Syndrome in a Two-Year-Old Boy: Case Report and Review of the Literature
  106. Response to initial treatment of multisystem langerhans cell histiocytosis: An important prognostic indicator
  107. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study
  108. Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children
  109. Treatment of Multisystem Langerhans Cell Histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 Studies
  110. Cyclosporine A therapy for multisystem Langerhans cell histiocytosis
  111. Cyclosporine A therapy for multisystem Langerhans cell histiocytosis
  112. Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients
  113. OCCURRENCE OF ACUTE NONLYMPHOBLASTIC LEUKEMIA IN TWO GIRLS AFTER TREATMENT OF RECURRENT, DISSEMINATED LANGERHANS CELL HISTIOCYTOSIS
  114. Transplantation activities and treatment strategies in paediatric stem cell transplantation centres: a report from the EBMT Working Party on Paediatric Diseases
  115. A single Centre Experience with allogeneic Stem Cell Transplantation for Severe Aplastic Anaemia in Childhood